Rezolute: Funding, Investors & Team (Oct 2026)
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio including RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
Rezolute has raised $331M across 4 funding rounds on record, the most recent an undisclosed round of $90.0M announced in Apr 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rezolute Company Profile and Key Stats
Latest funding round on record: Apr 2025.
Rezolute Funding Rounds
Rezolute raised $55.0M in a Post-IPO Equity announced in Oct 2021.
7 months later, a Post-IPO Equity of $130M was announced in May 2022.
2.1 years later, an undisclosed round of $56.4M was announced in Jun 2024.
10 months later, an undisclosed round of $90.0M was announced in Apr 2025.
Rezolute Founders and Leadership Team
Contact details for the Rezolute team: 2 of 2 have an email address on file.
Start 14-day free trial →Rezolute Funding Compared to Other Biotechnology Startups
Rezolute's latest round of $90.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rezolute in Biotechnology and Louisville
Companies Similar to Rezolute
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Rezolute Funding FAQs
What does Rezolute do?
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio including RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
How much funding has Rezolute raised?
Rezolute has raised $331M across 4 rounds on record. The most recent is an undisclosed round of $90.0M announced in Apr 2025.
When did Rezolute last raise funding?
Rezolute's most recent funding round on record is an undisclosed round of $90.0M, announced in Apr 2025.
Who founded Rezolute?
FundedIQ lists Nevan Elam (Founder) at Rezolute.
Who is the CEO of Rezolute?
Nevan Charles Elam is listed as CEO at Rezolute.
Where is Rezolute headquartered?
Rezolute is based in Louisville, Colorado, United States.
How many employees does Rezolute have?
Rezolute is in the 11-50 employee band.
How does Rezolute's funding compare to other Biotechnology startups?
Rezolute's latest round of $90.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Rezolute Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rezolute is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.